AUS
NZ
UK
CA
USA
IND
Highlights:
- Workforce and Strategy Overhaul: 23andMe cuts 40% of staff and halts therapeutics programs to focus on core genetics business, targeting $35 million in savings.
- Data Breach and Legal Settlement: A major breach affected 6.9 million users; the company settled for $30 million amid privacy concerns and international probes.
- Leadership Shakeup and Market Drop: Board resignations and a failed privatization plan led to a 70% stock plunge, cutting market value from $6 billion to under $200 million.
Genetic testing company 23andMe has announced plans to reduce its workforce by 40%, equating to approximately 200 positions, as part of a strategic initiative to stabilize its financial standing. This decision includes halting its therapeutics development programs, with intentions to license or divest these assets. The company anticipates incurring one-time costs of $12 million due to the layoffs but expects annual savings of over $35 million as a result.
This restructuring follows a tumultuous period for 23andMe, marked by a significant data breach that compromised the personal information of 6.9 million users. The breach, which occurred in 2023, involved unauthorized access to sensitive data, including family trees and geographic locations, though DNA records were reportedly not exposed. The incident led to investigations in the UK and Canada, highlighting concerns over data security and privacy.
In response to the breach, 23andMe agreed to a $30 million settlement to resolve a class-action lawsuit filed by affected customers. The settlement, which received preliminary approval in September 2024, aims to address the grievances of those whose personal information was compromised during the cyberattack.
The company has also experienced significant leadership changes, including the resignation of its independent board directors. These departures were reportedly due to disagreements with CEO Anne Wojcicki over her proposal to take the company private, a plan that faced criticism for not adequately benefiting non-affiliated shareholders.
Amid these challenges, 23andMe's stock has suffered a substantial decline, with shares plummeting over 70% in the past year. The company's market capitalization has dropped from a peak of $6 billion to below $200 million, reflecting investor concerns over its financial health and strategic direction.
Despite these setbacks, 23andMe remains committed to its core consumer business, focusing on providing genetic testing services to individuals. The company is seeking to rebuild trust with its customer base by enhancing data security measures and exploring new avenues for growth within the healthcare sector.
The recent workforce reduction and strategic shift away from therapeutics development underscore 23andMe's efforts to streamline operations and concentrate on its primary offerings. As the company navigates this period of transformation, its ability to adapt to evolving market conditions and address past vulnerabilities will be crucial in determining its future trajectory.
